<DOC>
	<DOCNO>NCT01085136</DOCNO>
	<brief_summary>The primary objective randomize , open-label , active-controlled , multi-center trial determine efficacy BIBW 2992 give add-on chemotherapy patient NSCLC Stage IIIb IV progress BIBW 2992 monotherapy compare chemotherapy alone patient population . Patients treatment arm receive best supportive care addition study treatment . Patients enrol trial treat follow death lose follow-up . Additional information health-related quality life ( HRQOL ) collect .</brief_summary>
	<brief_title>LUX-Lung 5 : Afatinib Plus Weekly Paclitaxel Versus Investigator 's Choice Single Agent Chemotherapy Following Afatinib Monotherapy Non-small Cell Lung Cancer Patients Failing Erlotinib Gefitinib</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Inclusion criterion : Part A 1 . Patients pathologically confirm diagnosis NSCLC Stage IIIB ( cytologically proven pleural effusion pericardial effusion ) Stage IV fail treatment erlotinib ( Tarceva ) gefitinib ( Iressa ) . 2 . Patients receive fail least one line cytotoxic chemotherapy include platinumbased regimen patient eligible platinumbased therapy pemetrexed pemetrexed eligible patient ( unless pemetrexed consider regulatory clinical standard care e.g . label indication , availability coverage 3rd party payer ( ) ) advance metastatic disease progressive disease follow least 12 week treatment erlotinib gefitinib 3 . Patients pretreated taxanebased chemotherapy advance metastatic disease must experience stable disease , partial complete response best response 4 . Eastern Cooperative Oncology Group performance Score 0 1 . 5 . Patients least one tumor lesion accurately measure magnetic resonance imaging ( MRI ) , compute tomography ( CT ) least one dimension long diameter record 10 mm less double slice thickness accord RESIST 1.1 . 6 . Male female patient le 18 year age . 7 . Life expectancy least three ( 3 ) month . 8 . Written inform consent consistent ICHGCP guideline . Part B 1 ) Clinical benefit ( disease stabilization antitumor response ) 12 week duration Part A trial determine second tumour assessment . 2 . ) Patients progress Part A accord RECIST 1.1 3 . ) New informed consent , include consent biomarker sampling , must sign patient enter Part B trial Exclusion criterion : 1 . Previous treatment BIBW 2992 2 . Chemo , hormone ( megestrol acetate , steroid require maintenance noncancer therapy premedication chemotherapy ) immunotherapy within past 4 week ; except TKI pretreatment ( 2 week ) 3 . Active/symptomatic brain metastasis include leptomeningeal disease . Patients history treat brain metastasis must stable normal brain MRT/CT scan screen least 4 week postradiation surgery brain metastasis . Dexamethasone therapy allow administer stable dose least one month randomization . 4 . Significant recent acute gastrointestinal disorder diarrhea major symptom e.g. , Crohn 's disease , malabsorption , CTCAE Grade &gt; 2 diarrhea etiology baseline 5 . Patients lifethreatening illness organ system dysfunction , opinion Investigator , would either compromise patient safety interfere evaluation safety test drug 6 . Other malignancy diagnose within past five ( 5 ) year ( nonmelanomatous skin cancer situ cervical cancer ) 7 . Radiotherapy within past 2 week prior treatment trial drug 8 . History presence clinically relevant cardiovascular abnormality uncontrolled hypertension , congestive heart failure New york Heart Association ( NYHA ) functional classification 3 , unstable angina , poorly control arrhythmia . Myocardial infarction within 6 month prior enter trial . 9 . Cardiac leave ventricular function rest ejection fraction le 50 % measure multigated blood pool image heart ( MUGA scan ) echocardiogram . 10 . Prior treatment anthracyclines cumulative dose doxorubicin ( equivalent ) great 400 mg/m2 11 . Absolute neutrophil count ( ANC ) less 1500 / mm3 12 . Platelet count le 100,000 / mm3 13 . Bilirubin great 1.5 mg / dL ( &gt; 26 mol / L , SI unit equivalent ) 14 . Aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) great three time upper limit normal ( related liver metastasis great five time upper limit normal ) 15 . Serum creatinine great 1.5 time upper normal limit calculated/measured creatinine clearance le 45 mL/min 16 . Women childbearing potential men able father child unwilling use medically acceptable method contraception trial 17 . Pregnancy breast feed 18 . Patients unable comply protocol 19 . Patients serious active infection include know human immunodeficiency virus ( HIV ) , active hepatitis B active hepatitis C 20 . Known suspected active drug alcohol abuse 21 . Preexisting current Interstitial lung disease ( ILD ) 22 . ) 22 . Peripheral polyneuropathy &gt; Grade 2 23 . Requirement treatment pohibited concomitant medication list section 4.2.2.1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>